These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Cyclophosphamide (NSC-26271) as adjuvant to radiotherapy in the treatment of unresectable bronchogenic carcinoma. Host H Cancer Chemother Rep 3; 1973 Mar; 4(2):161-4. PubMed ID: 4729319 [No Abstract] [Full Text] [Related]
43. Doxorubicin, vincristine, bleomycin, cytembena and cisplatin as combination chemotherapy for squamous cell lung cancer. Georgoulias V; Misset JL; Ribaud P; Machover D; De Vassal F; Dorval T; Musset M; Schwarzenberg L; Reizenstein P; Mathe G; Gaget H Anticancer Res; 1983; 3(2):107-10. PubMed ID: 6189445 [TBL] [Abstract][Full Text] [Related]
44. [Chemotherapy-cum-radiotherapy-cum-surgery in the treatment of small-cell bronchogenic carcinoma (author's transl)]. Gatzemeier U Prax Klin Pneumol; 1980 Feb; 34(2):102-7. PubMed ID: 7378158 [No Abstract] [Full Text] [Related]
45. Evaluation of the combination of hexamethylmelamine (NSC-13875) and methotrexate (NSC-740) in carcinoma of the lung. Weiss AJ; Wilson WL Cancer Chemother Rep; 1971 Jun; 55(3):299-302. PubMed ID: 5115850 [No Abstract] [Full Text] [Related]
46. Chemotherapy for inoperable, non-small cell bronchogenic carcinoma: EST 2575, generation II. Ruckdeschel JC; Mehta CR; Salazar OM; Cohen M; Vogl S; Koons LS; Lerner H Cancer Treat Rep; 1981; 65(11-12):965-72. PubMed ID: 7028258 [TBL] [Abstract][Full Text] [Related]
47. "CAMP" combination chemotherapy for unresectable non-oat cell bronchogenic carcinoma. Lad T; Sarma PR; Diekamp U; Tichler T; Chawla M; Krauss S; Zawila P; Nelson R Cancer Clin Trials; 1979; 2(4):321-6. PubMed ID: 394868 [TBL] [Abstract][Full Text] [Related]
48. CCNU, vincristine, methotrexate, and procarbazine treatment of relapsed small cell lung carcinoma. Poplin EA; Aisner J; Van Echo DA; Whitacre M; Wiernik PH Cancer Treat Rep; 1982 Jul; 66(7):1557-9. PubMed ID: 6284360 [TBL] [Abstract][Full Text] [Related]
49. Combined radiotherapy and multidrug chemotherapy for advanced head and neck cancer: results of a Radiation Therapy Oncology Group pilot study. Fu KK; Silverberg IJ; Phillips TL; Friedman MA Cancer Treat Rep; 1979 Mar; 63(3):351-7. PubMed ID: 85493 [TBL] [Abstract][Full Text] [Related]
50. Pilot study of multiple-fraction daily radiotherapy alternating with chemotherapy in patients with stage IV non-oat cell lung cancer. Arcangeli G; Righini R; Nervi C; Guerra A; Tirindelli D; Hopkins H; Looney W Cancer Treat Rep; 1985 Jan; 69(1):25-31. PubMed ID: 2981618 [TBL] [Abstract][Full Text] [Related]
51. [Chemotherapy of advanced head and neck cancer with a combination of bleomycin, vincristine, methotrexate and hydroxyuree or cis-dichloro-diamino-platinium. Analysis of local and general parameters of prognosis (author's transl)]. Pouillart P; Palangie T; Garcia-Giralt E; Jouve M; Bataini JP; Jaulerry M; Brugère J; Asselin B Bull Cancer; 1980; 67(3):269-80. PubMed ID: 6157447 [TBL] [Abstract][Full Text] [Related]
52. Multidrug chemotherapy (vincristine-bleomycin-methotrexate) followed by radiotherapy in inoperable carcinomas of the head and neck: a pilot study of the Radiation Therapy Oncology Group. Figueroa-Vallés NR; Marcial VA; Vélez-García E; Cintrón J; Vallecillo LA Am J Clin Oncol; 1982 Aug; 5(4):399-404. PubMed ID: 6180625 [TBL] [Abstract][Full Text] [Related]
53. Esophageal complications in the treatment of oat cell carcinoma with combined irradiation and chemotherapy. Chabora BM; Hopfan S; Wittes R Radiology; 1977 Apr; 123(1):185-7. PubMed ID: 191871 [TBL] [Abstract][Full Text] [Related]
54. Enhanced pulmonary toxicity with bleomycin and radiotherapy in oat cell lung cancer. Einhorn L; Krause M; Hornback N; Furnas B Cancer; 1976 May; 37(5):2414-6. PubMed ID: 56987 [TBL] [Abstract][Full Text] [Related]
55. [Combination treatment of small cell bronchial carcinoma]. Voss AC; Steinke B; Ostendorf P; Teller P; Gnann H Strahlentherapie; 1983 Jan; 159(1):18-21. PubMed ID: 6301108 [TBL] [Abstract][Full Text] [Related]
56. Evaluation of methotrexate in the treatment of bronchogenic carcinoma. Vincent RG; Pickren JW; Fergen TB; Takita H Cancer; 1975 Sep; 36(3):873-80. PubMed ID: 1182676 [TBL] [Abstract][Full Text] [Related]
57. Chemotherapy of lung cancer: the experience of the National Cancer Institute of Milan. Bonadonna G; Tancini G; Bajetta E Cancer Chemother Rep 3; 1973 Mar; 4(2):231-7. PubMed ID: 4125741 [No Abstract] [Full Text] [Related]
58. Comparison of two dose schedules of dichloromethotrexate (NSC-29630) in lung cancer. Band PR; Ross CA; Holland JF Cancer Chemother Rep; 1973 Feb; 57(1):79-82. PubMed ID: 4704106 [No Abstract] [Full Text] [Related]
59. Combined radiotherapy and chemotherapy versus radiotherapy alone in locally advanced epidermoid bronchogenic carcinoma. A randomized study. Trovò MG; Minatel E; Veronesi A; Roncadin M; De Paoli A; Franchin G; Magri DM; Tirelli U; Carbone A; Grigoletto E Cancer; 1990 Feb; 65(3):400-4. PubMed ID: 2404555 [TBL] [Abstract][Full Text] [Related]
60. Recent therapeutic developments in lung cancer. Hansen HH; Selawry OS Med Ann Dist Columbia; 1971 Sep; 40(9):580-2. PubMed ID: 4939062 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]